ADAR1 Capital Management LLC Grows Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

ADAR1 Capital Management LLC raised its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 15,557.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,174,313 shares of the company’s stock after acquiring an additional 1,166,813 shares during the quarter. ADAR1 Capital Management LLC owned approximately 3.36% of RAPT Therapeutics worth $1,855,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RAPT. Picton Mahoney Asset Management raised its stake in RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after buying an additional 14,697 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of RAPT Therapeutics by 9.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after acquiring an additional 18,558 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares during the period. Barclays PLC boosted its position in RAPT Therapeutics by 277.2% during the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in RAPT Therapeutics by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company’s stock worth $1,133,000 after acquiring an additional 33,758 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

RAPT Therapeutics Stock Down 4.5 %

Shares of RAPT Therapeutics stock opened at $1.06 on Monday. RAPT Therapeutics, Inc. has a 52-week low of $0.79 and a 52-week high of $9.65. The company has a 50 day moving average of $1.19 and a 200 day moving average of $1.43. The company has a market capitalization of $139.93 million, a P/E ratio of -0.38 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). As a group, research analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.